drugset
drugset / Trial / NCT06787131

Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers

NCT06787131 ↗

Phase 1 Completed 104 enrolled Lomond Therapeutics Holdings, Inc.
RandomizedSequentialDouble-blindTreatment

Summary

A first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of ZE50-0134 administered orally in healthy volunteers.

Timeline

Start
2024-05-21
Primary completion
2025-07-04
Completion
2025-07-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 200 mg —
Subject ZE50-0134 Unknown 100 mg Oral
Subject ZE50-0134 Unknown 200 mg Oral
Subject ZE50-0134 Unknown 400 mg Oral
Subject ZE50-0134 Unknown 800 mg Oral
Subject ZE50-0134 Unknown 1600 mg Oral
Background Rabeprazole Small molecule 20 mg —

Indications

No indication recorded.